Katrin Rupalla
Director/Board Member at 4D PHARMA PLC
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Daniel O'Connor | M | 59 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Axel Gaston Glasmacher | M | 64 |
The Cancer Drug Development Forum
| 5 years |
Christopher Boerner | M | 53 | 9 years | |
Phil Holzer | M | 48 | 11 years | |
Duncan Peyton | M | 54 | 10 years | |
Kate Hermans | F | 56 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Paul Maier | M | 76 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 3 years |
Alexander Stevenson | M | 53 | 10 years | |
Sonja Nelson | F | 51 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 3 years |
Edgardo Baracchini | M | 64 | 5 years | |
Santiago Arroyo | M | 64 | 3 years | |
Alexander Macrae | M | 61 | 5 years | |
Theodore Samuels | M | 69 | 7 years | |
Gregory Freitag | M | 62 | 1 years | |
Peter Arduini | M | 59 | 8 years | |
Bradley Bolzon | M | 64 |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Fritz Kunz | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Karen Vousden | M | 66 | 6 years | |
James Sapirstein | M | 63 | 1 years | |
Dorothea Wenzel | M | 55 | 3 years | |
Janet Loesberg | M | 61 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Peter Schiemann | M | - |
Ymmunobio AG
Ymmunobio AG BiotechnologyHealth Technology Ymmunobio AG is a Swiss preclinical stage oncology biotech company that develops innovative treatments for cancer patients through new classes of antibodies. The company is based in Riehen, Switzerland. The company focuses on high unmet need indications in gastro-intestinal cancers, making extensive progress in developing first-in-class or novel class of antibodies that have the potential to overcome resistance of cancer patients to current available therapies. Ymmunobio's research is based on their deep understanding of immuno-oncology and precision cancer treatments, leveraging their profound knowledge of biologics while selecting the optimal approach to developing transformative therapeutics across cancer indications. The company was founded in 2021 by Katrin Rupalla. The CEO is Peter Schiemann. | - |
Ernst H. Schweizer | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Janice Lu | M | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 2 years |
Christophe Carite | M | - | - | |
Tarek Samad | M | - | 3 years | |
Richard Avison | M | - | - | |
Samit Hirawat | M | 55 | 5 years | |
Zack Newman | M | - | 11 years | |
Stephen Glover | M | 60 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Nina Goworek | F | - | 6 years | |
Imke Mulder | F | - | - | |
Glenn Dourado | M | - | - | |
Andrew Aromando | M | 55 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Peter Herold | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Sharon Valdettaro | F | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Harald F. Schäfer | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Thomas Littke | M | 59 |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Michel Burnier | M | 71 |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Konrad P. Wirz | M | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Elisabeth Flury | F | - |
Speedel Pharma AG
Speedel Pharma AG Pharmaceuticals: MajorHealth Technology Speedel Pharma AG develops drugs for the treatment of cardiovascular and metabolic diseases. It researches on Renin Inhibitors and also develops an Endothelin Receptor Anatagonist. The company also operates in the U.S. and Japan. It was founded in 1998 and is headquartered in Basel, Switzerland. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Feng Tian | M | - |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 18 years |
Lamberto Andreotti | M | 73 | 19 years | |
James Cornelius | M | 81 | 10 years | |
Thomas Lynch | M | 63 | 5 years | |
John E. Celentano | M | 64 | 31 years | |
Togo Dennis West | M | 81 | 10 years | |
José Baselga | M | 65 | - | |
Jeffrey Jones | M | 53 | 5 years | |
Christian Nolet | M | 67 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | - |
John Tsai | M | 57 | 11 years | |
Jason Haddock | M | 54 | 14 years | |
Charles Sigal | M | 72 | 16 years | |
Carl Decicco | M | 62 | 10 years | |
Douglas Manion | M | 64 | 11 years | |
Olivia Ware | F | 67 |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | 1 years |
Dinesh C. Paliwal | M | 67 | 8 years | |
Brian Daniels | M | 65 | 14 years | |
David Robert Norwood | M | 56 | 6 years | |
Lewis B. Campbell | M | 77 | 18 years | |
Robert Bertolini | M | 61 | 4 years | |
Laurie Glimcher | M | 72 | 20 years | |
Béatrice J. Cazala | F | 67 | 32 years | |
Louis J. Freeh | M | 74 | 8 years | |
Matthew Emmens | M | 72 | 4 years | |
Robert Williams | M | 75 | 7 years | |
Lubor Gaal | M | 56 | 9 years | |
Nancy Phelan | F | 55 | 5 years | |
Anup Marda | M | 46 | 18 years | |
Joseph Eid | M | 56 | 4 years | |
Ronald Peck | M | 58 | 4 years | |
Karen LaRochelle | F | 57 | 20 years | |
Tamar Thompson | F | 50 | 4 years | |
Sanjay Keswani | M | 54 | 4 years | |
Anthony P Waclawski | M | 62 | 6 years | |
Jill Andersen | F | 51 | 4 years | |
JC Xu | M | 60 | 3 years | |
Vicki Goodman | M | 55 | 5 years | |
Laura Bessen | M | 61 | 15 years | |
Danielle Halstrom | F | - | 7 years | |
David Berman | M | - | 10 years | |
Kimberly Gentile | F | 56 | 14 years | |
Kinnari Patel | M | 46 | 4 years | |
Rupert Vessey | M | 59 | 8 years | |
Ranya Dajani | F | - | - | |
Michael Giordano | M | 66 | 18 years | |
Aditya Ash Damle | M | - | 2 years | |
Elliott Levy | M | 64 | 17 years | |
Joseph Leveque | M | 63 | 4 years | |
Saurabh Saha | M | 47 | 4 years | |
Michael Castagna | M | 47 | 2 years | |
John H. Lawrence | M | - | 18 years | |
Ronald Cooper | M | 61 | 7 years | |
Linda Kozick | F | 66 | 4 years | |
Lena Elisabeth Svanberg | M | 63 | 7 years | |
Charles Conway | M | 62 | 17 years | |
Frances K. Heller | F | 57 | - | |
Scott Gunther | M | 57 | 4 years | |
Kenzie Maclsaac | M | - | 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 75 | 75.76% |
United Kingdom | 11 | 11.11% |
Switzerland | 11 | 11.11% |
Denmark | 3 | 3.03% |
Belgium | 1 | 1.01% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Katrin Rupalla
- Personal Network